Education
About Us
Working with TipRanks
Follow Us
Amphastar Pharmaceuticals (DE:29A)
FRANKFURT:29A
RESEARCH TOOLSreports
29A Stock Chart & Stats
Day’s Range― - ―
52-Week Range€25.47 - €49.70
Previous CloseN/A
Volume0.00
Average Volume (3M)9.00
Market Cap
$1.27B
Enterprise Value€2.89B
Total Cash (Recent Filing)$201.38M
Total Debt (Recent Filing)$627.12M
Price to Earnings (P/E)9.1
Beta0.09
Next Earnings
May 07, 2025EPS Estimate
0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.83
Shares Outstanding47,650,120
10 Day Avg. Volume27
30 Day Avg. Volume9
Financial Highlights & Ratios
PEG Ratio0.58
Price to Book (P/B)N/A
Price to Sales (P/S)1.90
Price to Cash Flow (P/CF)5.70
P/FCF Ratio7.40
Enterprise Value/Market Cap2.28
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit7.74
Enterprise Value/Ebitda10.91
Forecast
1Y Price Target
€36.22Price Target Upside41.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
---
Amphastar Pharmaceuticals News
PremiumCompany Announcements
Amphastar’s Earnings Call: Growth Amid Challenges
PremiumCompany Announcements
Amphastar Pharmaceuticals Reports Strong 2024 Earnings
PremiumPre-Earnings
Is AMPH a Buy, Before Earnings?
---
Bulls Say, Bears Say
Bulls Say
Growth PotentialBaqsimi, a brand asset with higher margins than corporate margins, shows growth potential, which could help mitigate pressures from other product lines.
New Product LaunchesThe next 12 months could see 2-3 new product approvals, and AMPH has 2-3 more near-term potential launches in the pipeline that have been filed for regulatory review.
Bears Say
Competitive PressuresRecent competitive headwinds are affecting key products like injectable glucagon and injectable epinephrine, potentially pressuring Amphastar's top-line and EBITDA.
Regulatory ChallengesThe stock has been weak YTD (-28% vs. DRG +5%) as regulatory actions have pushed out potential launches.
Revenue DeclinesAMPH's 4Q24 top-line and bottom-line both came short of Street expectations, due to competitive pressures on glucagon, epinephrine and hospital products.
---
29A FAQ
What was Amphastar Pharmaceuticals’s price range in the past 12 months?
Amphastar Pharmaceuticals lowest stock price was €25.47 and its highest was €49.70 in the past 12 months.
What is Amphastar Pharmaceuticals’s market cap?
Amphastar Pharmaceuticals’s market cap is $1.27B.
When is Amphastar Pharmaceuticals’s upcoming earnings report date?
Amphastar Pharmaceuticals’s upcoming earnings report date is May 07, 2025 which is in 58 days.
How were Amphastar Pharmaceuticals’s earnings last quarter?
Amphastar Pharmaceuticals released its earnings results on Feb 27, 2025. The company reported €0.886 earnings per share for the quarter, missing the consensus estimate of €0.903 by -€0.017.
Is Amphastar Pharmaceuticals overvalued?
According to Wall Street analysts Amphastar Pharmaceuticals’s price is currently Undervalued.
Does Amphastar Pharmaceuticals pay dividends?
Amphastar Pharmaceuticals does not currently pay dividends.
What is Amphastar Pharmaceuticals’s EPS estimate?
Amphastar Pharmaceuticals’s EPS estimate is 0.66.
How many shares outstanding does Amphastar Pharmaceuticals have?
Amphastar Pharmaceuticals has 47,650,120 shares outstanding.
What happened to Amphastar Pharmaceuticals’s price movement after its last earnings report?
Amphastar Pharmaceuticals reported an EPS of €0.886 in its last earnings report, missing expectations of €0.903. Following the earnings report the stock price went down -5.313%.
Which hedge fund is a major shareholder of Amphastar Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:29A
---
Amphastar Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€36.22 (41.04% Upside)
€36.22 (41.04% Upside)
Blogger Sentiment
Bullish
DE:29A Sentiment 83%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.38%
12-Months-Change
Fundamentals
Return on Equity
23.26%
Trailing 12-Months
Asset Growth
7.36%
Trailing 12-Months
Company Description
Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products, and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets and distributes enoxaparin, cortrosyn, amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment manufactures and distributes recombinant human insulin and porcine insulin. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.
---
29A Company Deck
---
29A Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant revenue growth and strategic partnerships, especially for key products such as Primatene MIST and BAQSIMI. However, challenges such as decreasing glucagon sales, reduced gross margins, and increased competition were notable. The sentiment is balanced with optimism in pipeline developments countered by competitive and margin pressures.Read More>---
29A Stock 12 Month Forecast
Average Price Target
€36.22
▲(41.04% Upside)
Technical Analysis
Best Analysts Covering 29A
1 Year
1 Year Success Rate
11/18 ratings generated profit
1 Year Average Return
+12.01%
assigned a buy rating 5 months ago
Copying Tim Chiang's trades and holding each position for 1 Year would result in 61.11% of your transactions generating a profit, with an average return of +12.01% per trade.
---